ANDREW BRIGGLER MD NPI 1902284326

NPI Details

Andrew Briggler, MD is a hematology and oncology internal medicine in Little Rock, AR with 10 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Andrew Briggler, MD NPI is 1902284326. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF ARKANSAS COLLEGE OF MEDICINE
Graduation Year:2015

The provider's business location address is:

8901 CARTI WAY
LITTLE ROCK, AR
ZIP 72205-523
Phone: (501) 906-3000

The NPI 1902284326 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, decitabine, 1 mg (HCPCS:J0894)
• Injection, rituximab-abbs, biosimilar, (truxima), 10 mg (HCPCS:Q5115)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg (HCPCS:Q5108)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Follow-up hospital inpatient care per day, typically 15 minutes (HCPCS:99231)
• Ferritin (blood protein) level (HCPCS:82728)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Unclassified drugs (HCPCS:J3490)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Protein measurement, serum (HCPCS:84165)
• Nephelometry, test method using light (HCPCS:83883)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
• Erythropoietin (protein) level (HCPCS:82668)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Cortisol (hormone) measurement, total (HCPCS:82533)
• Coagulation function measurement, d-dimer; quantitative (HCPCS:85379)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• Folic acid level, serum (HCPCS:82746)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Established patient office or other outpatient visit, 10-19 minutes (HCPCS:99212)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Injection of drug or substance into vein (HCPCS:96374)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Administration of influenza virus vaccine (HCPCS:G0008)

The enumeration date for this NPI number is 5/18/2015 and was last updated on 3/30/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: